ENHANCED TUMOR-NECROSIS-FACTOR SUPPRESSION AND CYCLIC ADENOSINE-MONOPHOSPHATE ACCUMULATION BY COMBINATION OF PHOSPHODIESTERASE INHIBITORS AND PROSTANOIDS

Citation
B. Sinha et al., ENHANCED TUMOR-NECROSIS-FACTOR SUPPRESSION AND CYCLIC ADENOSINE-MONOPHOSPHATE ACCUMULATION BY COMBINATION OF PHOSPHODIESTERASE INHIBITORS AND PROSTANOIDS, European Journal of Immunology, 25(1), 1995, pp. 147-153
Citations number
44
Categorie Soggetti
Immunology
ISSN journal
00142980
Volume
25
Issue
1
Year of publication
1995
Pages
147 - 153
Database
ISI
SICI code
0014-2980(1995)25:1<147:ETSACA>2.0.ZU;2-O
Abstract
We investigated cooperative effects of phosphodiesterase (PDE) inhibit ors and prostanoids on cyclic adenosine monophosphate (cAMP) accumulat ion and tumor necrosis factor (TNF)-alpha synthesis in human periphera l blood mononuclear cells (PBMC). PDE inhibitors alone induced only a small increase in cAMP levels in lipopolysaccharide (LPS)-stimulated P BMC. Cicaprost (a stable analogue of prostacyclin) and pentoxifylline added simultaneously to LPS-stimulated PBMC (2.0 x 10(6)/ml) induced a rapid increase of cAMP to a level of 100 nM that peaked within 10 min and remained at a plateau for up to 4 h. Thus combined prostanoids an d PDE inhibitors enhanced cAMP accumulation. TNF-alpha suppression in the presence of pentoxifylline and prostanoids exceeded that of either drug alone. The potency of different PDE inhibitors (theophylline, pe ntoxifylline, penthydroxifylline, albifylline, torbafylline, A 80 2715 , amrinone and rolipram) to increase cAMP levels in combination with c icaprost was evaluated after 1 h of incubation. The dose-dependent inc rease of cAMP for all PDE inhibitors tested in this combined stimulati on provided a useful tool for evaluating the potency of PDE inhibitors on cAMP accumulation. The effective concentration of PDE inhibitors, which raised cAMP levels to 300% of control, (EC(300)), correlated wit h the IC50 for TNF-alpha suppression (r = 0.930, p = 0.007, with theop hylline excluded from the analysis). Interestingly, by contrast, the s pecific type IV PDE inhibitor rolipram caused only a moderate rise of accumulated cAMP in the same cells. Our data support cAMP as an essent ial mediator for TNF-alpha suppression by PDE inhibitors. Furthermore, an enhanced inhibiting effect on TNF-alpha production may prove thera peutically advantageous. It may occur in inflammatory and infectious d iseases in vivo, since high levels of endogenous prostaglandins are li berated in these conditions.